> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music
> LIsten on iHeart
> Watch on YouTube
In this episode of Denatured, you’ll listen to Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak,
president, CEO and board director at Candel Therapeutics. We investigate how intratumoral therapies can generate systemic antitumor immune responses from a localized injection, advancing a foundational platform in immuno-oncology.
Host
Jennifer C. Smith-Parker, Director of Insights, BioSpace
Guests
Lewis Bender, President & CEO, Intensity Therapeutics
Paul-Peter Tak, President, CEO and Board Director, Candel Therapeutics
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
